Apiotix Technologies

logo Apiotix



Apiotix has created a unique, standardized propolis extract called Apimast, characterized by HPLC-UV and reproducible. Apimast is based on a patented extraction and standardization method described in the LIQUID PROPOLIS EXTRACT, ITS FORMULATION, AND USE THEREOF patent.

Clinical Development - Proof of Concept Studies:

Between 2014 and 2016, preliminary data on Apimast’s effectiveness in treating subclinical mastitis in lactating cows were gathered from five commercial dairy farms. The results demonstrated the extract’s antibacterial and antioxidant properties, with Apimast proving safe and effective at 1% (85% cure rate) and 3% (100% cure rate) concentrations. Apimast underwent further examination through a series of studies, including an experimental Staphylococcus aureus mastitis model, two field clinical trials in lactating cows for subclinical and clinical mastitis, and a dry-off safety and efficacy trial. In all trials, Apimast exhibited safety, tolerability, and substantial efficacy.

In Vitro Data:

Numerous in vitro studies were conducted to evaluate Apimast’s effectiveness, including MIC, MBEC, antioxidant assays (FRAP and DHPP), 12-cell inflammation models, MTT assay, keratinocyte scratch test, and antibacterial mode of action. Apimast’s mechanism of action positions it as a natural anti-inflammatory, antioxidant, and antimicrobial extract with demonstrated efficacy in vitro and in vivo.

Next Steps:

To register Apimast as a veterinary medicinal product (VMP) for mastitis treatment and prevention during lactation and dry-off, we need to:

  1. Complete GMP development of the API and final product, leveraging the simple production process and straightforward standardization method for easy quality control.
  2. Conduct two pivotal studies with the GMP intramammary product, focusing on lactation (clinical mastitis) and dry-off.

What Are We Looking For?

We seek strategic partners and investors (VCs, corporate, impact, angel) with expertise in animal health, veterinary medicine, or related fields to help finalize Apimast’s development for market entry. Additionally, we are open to collaboration with research institutions, universities, and other SMEs. Our work is grounded in 15 years of scientific research, which has yielded several PhDs, graduate theses, and academic publications. Our passion for science drives us to address critical global challenges such as antimicrobial resistance and antibiotic overuse through unbiased research.